{"filing":{"accession_number":"0001437749-26-021041","cik":"0000925741","ticker":"BCDA","company_name":"BioCardia, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"bcda20260617_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774926021041/bcda20260617_8k.htm"},"events":[{"id":11706,"run_id":10289,"accession_number":"0001437749-26-021041","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"This is a shareholder letter disclosing strategic business updates, regulatory milestones, and capital allocation plans following a recent capital raise. While it contains forward-looking statements about regulatory submissions (CardiAMP PMDA submission in Q4 2026), clinical trial enrollment, and partnership opportunities, it does not constitute a discrete material event from the taxonomy (not an earnings release, M\u0026A activity, executive change, impairment, covenant breach, or other specific event type). The disclosure is material to investors as it outlines near-term catalysts and business strategy, but the Item 7.01 Regulation FD format and content—a strategic update rather than a specific triggering event—best fits \"other_material.\"","company_name":"BioCardia, Inc.","ticker":"BCDA","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8361,"accession_number":"0001437749-26-021041","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"This is a shareholder letter disclosing strategic business updates, regulatory milestones, and capital allocation plans following a recent capital raise. While it contains forward-looking statements about regulatory submissions (CardiAMP PMDA submission in Q4 2026), clinical trial enrollment, and partnership opportunities, it does not constitute a discrete material event from the taxonomy (not an earnings release, M\u0026A activity, executive change, impairment, covenant breach, or other specific event type). The disclosure is material to investors as it outlines near-term catalysts and business strategy, but the Item 7.01 Regulation FD format and content—a strategic update rather than a specific triggering event—best fits \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:02:15.554338+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8361,"accession_number":"0001437749-26-021041","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"This is a shareholder letter disclosing strategic business updates, regulatory milestones, and capital allocation plans following a recent capital raise. While it contains forward-looking statements about regulatory submissions (CardiAMP PMDA submission in Q4 2026), clinical trial enrollment, and partnership opportunities, it does not constitute a discrete material event from the taxonomy (not an earnings release, M\u0026A activity, executive change, impairment, covenant breach, or other specific event type). The disclosure is material to investors as it outlines near-term catalysts and business strategy, but the Item 7.01 Regulation FD format and content—a strategic update rather than a specific triggering event—best fits \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:02:15.554338+00:00","company_name":"BioCardia, Inc.","ticker":"BCDA","filing_date":"2026-06-18"}]}